Compare Duke Energy Corp (DUK) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Organon & Co. Common Stock — how do they compare? Duke Energy Corp trades at $120.43 (market cap $92.15B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Duke Energy Corp is far larger — about 25.5× Organon & Co. Common Stock's market cap, and Duke Energy Corp pays the higher dividend (3.67%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 75 Days and Organon & Co. Common Stock for 0 Days on average.
| DUK | OGN | |
|---|---|---|
Market Cap | $92.15B | $3.62B |
Volume | 3,498,824 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $133.46 | $13.81 |
52-Week Low | $113.23 | $5.70 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $184.66B | $11.04B |
Dividend Yield | 3.67% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $119.64, up 1.66% on the day, with a bullish technical signal despite some overbought RSI readings. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $32.24B and $4.97B in 2025, respectively, while maintaining strong profitability margins. Recent news highlights dividend declarations and data center growth opportunities.
The outlook for DUK is positive, supported by consistent earnings beats, a solid dividend yield, and strategic positioning in data center contracts. Risks include high debt levels, rising interest rates impacting utility stocks, and execution challenges in capital-intensive projects. Analyst consensus leans hold with a $131.50 price target, suggesting moderate upside from current levels.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
